Search Bar & Filters
Found 15 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of NNC0487-0111 in people who have excess body weight and knee osteoarthritis. This study compares two doses of NNC0487-0111 given as weekly injections under the skin against a placebo, with the goal of helping participants lose weight and reduce knee pain. Participants have knee osteoarthritis confirmed by clinical and radiographic criteria and will follow a reduced-calorie diet and increased physical activity throughout the study. Participants will be randomly assigned to receive one of three treatments NNC0487-0111 dose level 1, NNC0487-0111 dose level 2, or a placebo, all given once weekly by subcutaneous injection using a pre-filled pen injector. The injections will be administered to the thigh, abdomen, or upper arm. All participants will be encouraged to follow a reduced-calorie diet and increase physical activity during the trial. The treatment period lasts for 80 weeks. Throughout the study, participants will have regular assessments of body weight, knee pain, physical function, and other health measures. Researchers will collect data on changes in weight, knee pain scores using the WOMAC index, physical function, blood pressure, cholesterol levels, blood sugar markers, and use of pain medication. Safety will be monitored through reporting of adverse events. The study is expected to continue until August 2028, with visits and evaluations occurring at scheduled intervals during the treatment period.
Actively Recruiting
Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.
Actively Recruiting
Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.
Actively Recruiting
Researchers are studying the effects of orforglipron compared to a placebo in adults aged 50 and older who have atherosclerotic cardiovascular disease ASCVD andor chronic kidney disease CKD. This Phase 3 trial aims to evaluate how orforglipron impacts major cardiovascular events over about five years of participation. Participants will be randomly assigned to receive either orforglipron orally along with standard care or a placebo orally with standard care. The study is double-blind, meaning neither participants nor researchers know who receives the active drug or placebo. This design helps measure the drugs impact on cardiovascular health and kidney function over the study duration. During the study, participants will be monitored regularly to track the time to the first major cardiovascular event and other health outcomes such as kidney function changes and the onset of type 2 diabetes. The study involves ongoing assessments from baseline through the five-year period, including follow-ups to ensure safety and gather detailed health information.
Actively Recruiting
Researchers are evaluating three different surgical techniques of lateral internal sphincterotomy LIS for patients with chronic anal fissure that has not improved with medical treatment. The study aims to compare the healing rates and the occurrence of fecal incontinence among these techniques over 12 months. This trial is a prospective randomized controlled study involving 150 adult patients, assessing how different extents of sphincterotomy affect outcomes. The three techniques being compared are Spasm-Controlled LIS, which uses serial small sphincterotomies under local anesthesia and sedation until a target anal canal size is reached LIS up to the Fissure Apex, an open procedure under spinal or general anesthesia extending to the fissures end and LIS up to the Dentate Line, the traditional open method extending to the dentate line, also under spinal or general anesthesia. Randomization assigns patients equally to one of these groups, and all surgeries are performed with an open technique in the lithotomy position. Participants will be evaluated before surgery and at several points after surgery including day 1, weeks 1 and 2, and months 1, 2, 6, and 12. Researchers will use the Wexner Incontinence Score to assess continence and will check for fissure healing, pain levels, recurrence, patient satisfaction, and complications. The study includes careful monitoring to compare the effectiveness and safety of the different surgical approaches over a full year.
Actively Recruiting
Healthy Volunteer
This research aims to compare the effects of two types of muscle trainingperipheral muscle training and inspiratory muscle trainingcombined with aerobic exercise on muscle strength, physical performance, respiratory muscle strength, functional capacity, sarcopenia, and quality of life in older adults. It focuses on geriatric individuals aged 65 to 80 years, who often experience declines in muscle strength, respiratory function, and physical activity, increasing their risk for health problems and disability. The study addresses gaps in previous research by combining aerobic and strengthening exercises for this population. Participants will be randomly assigned to one of two groups. One group will engage in group exercise training that includes aerobic and resistance training twice a week for ten weeks, with each session lasting one hour and supervised by a physiotherapist. The other group will perform the same aerobic and resistance training schedule, plus inspiratory muscle training involving 30 breathing cycles per day, six days a week, for ten weeks, with two sessions in the clinic and four sessions at home. During the study, participants will be assessed on various measures including hand grip strength, maximal inspiratory and expiratory pressures, the 6-Minute Walk Test, and the Short Physical Performance Battery over ten weeks. Quality of life will be evaluated using the WHOQOL-OLD questionnaire, and sarcopenia will be assessed with the SARC-F questionnaire. Researchers will monitor participant progress and outcomes throughout the intervention period to evaluate the impact of each training method on physical and respiratory function.
Actively Recruiting
Researchers are evaluating depemokimab as a treatment for adults with moderate to severe chronic obstructive pulmonary disease COPD who have type 2 inflammation and uncontrolled symptoms. This Phase 3 study aims to assess the effectiveness and safety of depemokimab when added to standard care for these patients. The focus is on reducing COPD exacerbations and improving respiratory health. Participants will be randomly assigned to receive either depemokimab or a placebo along with their usual COPD treatments. Depemokimab is given as a sterile liquid formulation, and the study compares its effects against placebo over a period of up to 104 weeks. Both groups continue their optimized inhaler therapy during the trial. During the study, participants will undergo regular assessments including lung function tests, symptom questionnaires like the COPD assessment test CAT, and monitoring of exacerbations. Researchers will measure outcomes such as the rate of moderate or severe exacerbations annually and changes in respiratory symptoms. Safety and overall health are closely followed throughout the two-year treatment period.
Actively Recruiting
Healthy Volunteer
Effective management of dental caries in primary teeth is important for relieving pain, preventing infection, and maintaining a childs overall health. This research aims to compare three methodsFluorescence-Aided Caries Excavation FACE, caries detection dye, and clinical observationto see which best detects leftover caries on cavity walls after Atraumatic Restorative Treatment ART. ART is a minimally invasive treatment often used in children that removes decay without rotary tools and fills cavities with glass ionomer cement, but detecting residual caries can be challenging. Children aged 4 to 9 years who are healthy and cooperative will have their primary molars examined in six cavity wall regions. The study compares residual caries detection using FACE with the D-light Pro GC device, caries detection dye, and clinical observation in a randomized, double-blinded manner. If any method finds residual caries, additional removal is done before final restoration with high-viscosity glass ionomer cement following ART protocols. Participants will undergo examination during a single visit lasting up to 10 minutes. Two independent observers will record if caries are present or absent on each cavity wall for statistical analysis. Data on age, gender, tooth location, tooth type, and dental health index will also be collected. The primary outcome measures focus on detection accuracy immediately after caries removal, with no follow-up visits required. This study seeks to guide clinicians in improving long-term success of ART in children.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating how traditional behavior management techniques compare to AI-assisted child-friendly communication in reducing dental anxiety, physiological stress, and pain perception during local anesthesia in healthy children aged 6 to 12 years. The study focuses on children undergoing dental procedures requiring inferior alveolar nerve block anesthesia and aims to improve pediatric dental treatment comfort and outcomes by integrating AI tools. Participants will be randomly assigned to either a control group using traditional techniques like Tell-Show-Do, voice control, and positive reinforcement, or an experimental group using AI-generated voice explanations and calming stories tailored to the childs age, gender, and developmental stage. The traditional procedure and AI-assisted communication both occur during a local anesthesia process not exceeding 5 minutes. Childrens heart rate and oxygen levels will be measured before, during, and after anesthesia using a pulse oximeter. Anxiety will be assessed with various scales including the Venham Picture Test and Facial Image Scale, while pain perception will be measured using the Wong-Baker FACES Pain Rating Scale. Behaviors during anesthesia and cooperation levels will also be recorded. Both children and parents will complete questionnaires after treatment to evaluate attitudes toward AI communication. The total study participation includes these assessments and monitoring during the procedure.
1-10 of 15
1